Atea Pharmaceuticals (AVIR) Income towards Parent Company: 2019-2024
Historic Income towards Parent Company for Atea Pharmaceuticals (AVIR) over the last 6 years, with Dec 2024 value amounting to -$168.4 million.
- Atea Pharmaceuticals' Income towards Parent Company fell 129.40% to -$34.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$115.9 million, marking a year-over-year decrease of 195.64%. This contributed to the annual value of -$168.4 million for FY2024, which is 23.85% down from last year.
- As of FY2024, Atea Pharmaceuticals' Income towards Parent Company stood at -$168.4 million, which was down 23.85% from -$136.0 million recorded in FY2023.
- Atea Pharmaceuticals' 5-year Income towards Parent Company high stood at $121.2 million for FY2021, and its period low was -$168.4 million during FY2024.
- Its 3-year average for Income towards Parent Company is -$140.1 million, with a median of -$136.0 million in 2023.
- In the last 5 years, Atea Pharmaceuticals' Income towards Parent Company spiked by 1,207.06% in 2021 and then plummeted by 195.64% in 2022.
- Atea Pharmaceuticals' Income towards Parent Company (Yearly) stood at -$10.9 million in 2020, then surged by 1,207.06% to $121.2 million in 2021, then crashed by 195.64% to -$115.9 million in 2022, then fell by 17.30% to -$136.0 million in 2023, then fell by 23.85% to -$168.4 million in 2024.